3 completed, 1 terminated. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Terminated 1 |
Follow CERC-501: new trials by email Literature Review of CERC-501 trials Research Report on CERC-501
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Does CERC-501 Attenuate Stress-precipitated Smoking Lapse? CERC-501, Placebo - Smoking | Phase 2 | Completed | Yale University | 17 | 2016-06-30 | 2019-08-13 |
| A Study in a Human Laboratory Model of Smoking Behavior CERC-501, Placebo - Smoking | Phase 2 | Completed | Janssen Research & Development, LLC | 71 | 2015-12-31 | 2025-04-27 |
| Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a CERC-501, placebo - ANXIETY DISORDERS (or Anxiety and Phobic Neuroses) | Phase 2 | Completed | Duke University | 163 | 2015-06-01 | 2019-01-08 |
| Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression CERC-501, Placebo - Treatment Resistant Depression | Phase 2 | Terminated | Massachusetts General Hospital | 8 | 2013-09-12 | 2017-07-02 |
Smoking (2) · Anhedonia (1) · Anxiety Disorders (1) · Depression (1) · Depressive Disorder, Major (1) · Depressive Disorder, Treatment-Resistant (1) · Phobic Disorders (1)
Duke University (1) · Janssen Research & Development, LLC (1) · Massachusetts General Hospital (1) · Yale University (1)
United States (4)
John Zajecka, MD (1) · Linda L Carpenter, MD (1) · Mary F Morrison, MD (1) · Matthew Macaluso, DO (1) · Maurizio Fava, MD (1) · Richard D Weiner, MD, PhD (1) · Ronald Marcus, MD (1) · Sherry McKee, PhD (1)
271201100006I-0-27100007-1 (1), P50DA033945 (1)